Evidence map›Paper›PMID 37089147›Full record

ReviewIranian journal of public health2023

Antifungal Resistance of Clinical

Firoozeh Kermani, Mojtaba Taghizadeh-Armaki, Seyed Abdollah Hosseini, Nasrin Amirrajab, Javad Javidnia, Mahmoud Fami Zaghrami, Tahereh Shokohi

Open access · goldAbstract readReview
In one paragraph

Review in Iranian journal of public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Twenty-Year Course of Antifungal Resistance inJournal of fungi (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Antifungal susceptibility profiles ofMicrobiology spectrum · 2025
    Article
  6. Evaluation of the antagonistic effect ofIranian journal of microbiology · 2025
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Firoozeh KermaniInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mojtaba Taghizadeh-ArmakiDepartment of Medical Parasitology and Mycology, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
Seyed Abdollah HosseiniToxoplasmosis Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Nasrin AmirrajabDepartment of Laboratory Sciences' School of Allied Medical Sciences' Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Javad JavidniaStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Mahmoud Fami ZaghramiKnowledge-Based Darui Daneshgar Zolang Respina Pharmaceutical Company, Sari, Iran.
Tahereh ShokohiInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mazandaran University of Medical Sciences · IRBabol University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The present systematic review aimed to investigate the drug susceptibility patterns of Iranian clinical Methods: Six electronic databases including "PubMed," "Scopus," "Web of Science," "IranDoc", "SID", and "Magiran" were searched from May 2000 to June 2021. The susceptibility of 6322 Results: The pooled prevalence of antifungal resistance ranged from 0% to 26%. The lowest resistance levels among azoles were observed in luliconazole with a frequency of 0% and voriconazole of 3.94%. Conclusion: Due to the emergence of multi-drug resistant

Indexed as

Antifungal susceptibilityCandida albicansMulti-drug resistance

Identifiers

PMID37089147
PMCPMC10113589
OpenAlexW4319438125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.